Disclosure in term of regulation 31(4) of the SEBI (SAST) Regulation 2011
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has filed the mandatory yearly disclosure under SEBI's Takeover Regulations confirming that no encumbrance (pledge or charge) was created on shares held by promoter group members during FY2024-25. The disclosure was submitted by six individuals from the promoter family – Jayshree Bhaskar Sandu, Shashank B Sandu, Minal Shashank Sandu, Umesh B Sandu, Geeta Umesh Sandu, and Shubhada Prabhakar Sandu – along with promoter group entity Akshath Finvest and Properties Pvt Ltd. Each of them has confirmed that as of 31 March 2025, the number of shares encumbered or pledged by them in the company stands at nil. The company has been asked to place the disclosure before the next Audit Committee meeting.
This is a routine compliance filing with no change in promoter shareholding or pledge status. It signals that the promoter group has not used their shares as collateral, which is a neutral-to-positive indicator of promoter confidence and financial stability. No material impact on the stock is expected.